AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25588294 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1246
Study 25588294 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo pill plus placebo patch)
Number of subjects: 1246
Study 24175463 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous exercise before vocabulary recall and comprehension learning activity
Number of subjects: 90
Study 24175463 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous exercise after vocabulary recall and comprehension learning activity
Number of subjects: 90
Study 24175463 — intervention group
Group type: COMPARATOR
Intervention: Moderate exercise
Number of subjects: 90
Study 24175463 — intervention group
Group type: COMPARATOR
Intervention: No physical exercise
Number of subjects: 90
Study 21430090 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (education and exercise training) for 3 months
Number of subjects: 251
Study 21430090 — intervention group
Group type: COMPARATOR
Intervention: High fatigue group
Number of subjects: 251
Study 19075276 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl palmitate (RP) plus beta-carotene (BC)
Number of subjects: 162
Study 19075276 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl palmitate (RP) alone
Number of subjects: 162
Study 19075276 — intervention group
Group type: COMPARATOR
Intervention: Low-dose 13-cis retinoic acid (13cRA)
Number of subjects: 162
Study 19075276 — intervention group
Group type: COMPARATOR
Intervention: Grades 2 and higher adverse events
Number of subjects: 162
Study 17098749 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (varied levels)
Number of subjects: 1691
Study 17098749 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking frequency
Number of subjects: 1691
Study 15121121 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermagraft and compression therapy
Number of subjects: 18
Study 15121121 — intervention group
Group type: COMPARATOR
Intervention: Compression therapy alone
Number of subjects: 18
Study 11602028 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (3, 6, or 9 mg/d)
Number of subjects: 27
Study 11602028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 11602028 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine responders
Number of subjects: 27
Study 11602028 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine non-responders
Number of subjects: 27
Study 11602028 — intervention group
Group type: COMPARATOR
Intervention: Placebo-treated patients
Number of subjects: 27
Study 9158266 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment (50 micrograms/g)
Number of subjects: 122
Study 9158266 — intervention group
Group type: COMPARATOR
Intervention: Coal tar/2% allantoin/0.5% hydrocortisone cream
Number of subjects: 122
Study 7701788 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (patients with hereditary factors)
Number of subjects: 1119
Study 7701788 — intervention group
Group type: COMPARATOR
Intervention: Group II (controls)
Number of subjects: 1119
Study 3284406 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.008 mg/kg)
Number of subjects: 0
Study 3284406 — intervention group
Group type: COMPARATOR
Intervention: Morphine (0.333 mg/kg)
Number of subjects: 0
Study 30016477 — intervention group
Group type: EXPERIMENTAL
Intervention: SPEEK programme (11 interactive lessons)
Number of subjects: 1822
Study 30016477 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 1822
Study 26882111 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional care bridge program intervention
Number of subjects: 674
Study 26882111 — intervention group
Group type: COMPARATOR
Intervention: CGA-only arm
Number of subjects: 674
Study 25398799 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 100 mg
Number of subjects: 12
Study 25398799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 22154798 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting
Number of subjects: 411
Study 22154798 — intervention group
Group type: COMPARATOR
Intervention: On-pump coronary artery bypass grafting
Number of subjects: 411
Study 20545688 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic milk containing Lactobacillus rhamnosus GG, L. acidophilus La‐5, and Bifidobacterium animalis subsp. lactis Bb‐12
Number of subjects: 415
Study 20545688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study 20545688 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic milk
Number of subjects: 415
Study 18462811 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 28
Study 18462811 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 28
Study 18462811 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with major depression
Number of subjects: 28
Study 15144477 — intervention group
Group type: COMPARATOR
Intervention: Double-blind placebo-controlled food challenges (DBPCFCs) to cow's milk, hen's egg, wheat, and soy
Number of subjects: 64
Study 15144477 — intervention group
Group type: COMPARATOR
Intervention: Food-specific IgE and APT
Number of subjects: 64
Study 12138268 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprammonium (CU) dialyser
Number of subjects: 8
Study 12138268 — intervention group
Group type: COMPARATOR
Intervention: Polysulfon (PS) dialyser
Number of subjects: 8
Study 11475719 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlid 250 mg orally, once a day
Number of subjects: 58
Study 11475719 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax notoginseng (PNG) 8 ml in 250 ml of normal saline intravenous drip once a day
Number of subjects: 58
Study 7644096 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐IFN (3,000,000 UI i.m. on alternate days for 4 weeks)
Number of subjects: 94
Study 7644096 — intervention group
Group type: COMPARATOR
Intervention: alpha‐2A‐IFN (3,000,000 UI i.m. on alternate days for 4 weeks)
Number of subjects: 94
Study 2612535 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal 4 g/day
Number of subjects: 17
Study 2612535 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal 8 g/day
Number of subjects: 17
Study 2612535 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal 16 g/day
Number of subjects: 17
Study 2612535 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal 32 g/day
Number of subjects: 17
Study 2612535 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine 16 g
Number of subjects: 17
Study 2612535 — intervention group
Group type: COMPARATOR
Intervention: Activated charcoal 8 g + cholestyramine 8 g
Number of subjects: 17
Study 2612535 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal
Number of subjects: 17
Study 2612535 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine
Number of subjects: 17
Study 2612535 — intervention group
Group type: COMPARATOR
Intervention: Activated charcoal + cholestyramine
Number of subjects: 17
Study 122071 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG) added to existing bronchodilators and/or steroid therapy
Number of subjects: 0
Study 122071 — intervention group
Group type: COMPARATOR
Intervention: Control group (existing bronchodilators and/or steroid therapy without DSCG)
Number of subjects: 0
Study 30592662 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention
Number of subjects: 319
Study 30592662 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 319
Study 28847455 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis Use Reduction (n=152)
Number of subjects: 302
Study 28847455 — intervention group
Group type: COMPARATOR
Intervention: Cannabis Use Increase (n=150)
Number of subjects: 302
Study 26042589 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 5 mg
Number of subjects: 355
Study 26042589 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 25 mg
Number of subjects: 355
Study 26042589 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Number of subjects: 355
Study 26042589 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg
Number of subjects: 355
Study 26042589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study 23942558 — intervention group
Group type: EXPERIMENTAL
Intervention: HRC display monitoring
Number of subjects: 2989
Study 23942558 — intervention group
Group type: COMPARATOR
Intervention: Nondisplay group
Number of subjects: 2989
Study 22375409 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangai injection plus FLAG regimen
Number of subjects: 49
Study 22375409 — intervention group
Group type: COMPARATOR
Intervention: FLAG regimen
Number of subjects: 49
Study 19114859 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg twice daily
Number of subjects: 821
Study 19114859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 821
Study 19114859 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age at enrolment (age 16-19)
Number of subjects: 821
Study 19114859 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption at enrolment (> or =30 drinks/week)
Number of subjects: 821
Study 19114859 — intervention group
Group type: EXPERIMENTAL
Intervention: Paid sex within the previous 3 months
Number of subjects: 821
Study 19114859 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent infection with gonorrhoea
Number of subjects: 821
Study 19114859 — intervention group
Group type: EXPERIMENTAL
Intervention: Injections in the previous 3 months
Number of subjects: 821
Study 19114859 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in the recruitment community for less than 2 years
Number of subjects: 821
Study 19114859 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to hormonal contraception
Number of subjects: 821
Study 16444457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide
Number of subjects: 150
Study 16444457 — intervention group
Group type: COMPARATOR
Intervention: Acenocoumarol
Number of subjects: 150
Study 14557887 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment for infections, allergies, gastroesophageal reflux, and environmental irritants.
Number of subjects: 30
Study 14557887 — intervention group
Group type: COMPARATOR
Intervention: Medical voice-hygiene advice including the use of the Accent method.
Number of subjects: 30
Study 14557887 — intervention group
Group type: COMPARATOR
Intervention: Retrospective group treated medically.
Number of subjects: 30
Study 14557887 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonetograms measured in all groups.
Number of subjects: 30
Study 11434830 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (n=5476)
Number of subjects: 8555
Study 11434830 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=3079)
Number of subjects: 8555
Study 11434830 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (n=4680, excluding EPIC bolus-only group)
Number of subjects: 8555
Study 11434830 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=3023, excluding EPIC bolus-only group)
Number of subjects: 8555
Study 11434830 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 8555
Study 11434830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8555
Study 11434830 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab with standard-dose heparin
Number of subjects: 8555
Study 9627510 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile acids (ursodeoxycholic acid 500 mg and chenodeoxycholic acid 500 mg per day)
Number of subjects: 102
Study 9627510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 9627510 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile acids (ursodeoxycholic acid and chenodeoxycholic acid)
Number of subjects: 102
Study 9627510 — intervention group
Group type: COMPARATOR
Intervention: Bile acids and Placebo
Number of subjects: 102
Study 7889908 — intervention group
Group type: EXPERIMENTAL
Intervention: Program E (Health Belief Model)
Number of subjects: 295
Study 7889908 — intervention group
Group type: EXPERIMENTAL
Intervention: Program EP (Health Belief Model + social psychology of compliance exercises)
Number of subjects: 295
Study 7889908 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 295
Study 3622581 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 8
Study 3622581 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg)
Number of subjects: 8
Study 3622581 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 8
Study 3622581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29020321 — intervention group
Group type: EXPERIMENTAL
Intervention: SII RMAb
Number of subjects: 200
Study 29020321 — intervention group
Group type: COMPARATOR
Intervention: HRIG
Number of subjects: 200
Study 27788416 — intervention group
Group type: EXPERIMENTAL
Intervention: TPB‐based intervention programme (individual instruction, group education, telephone counselling)
Number of subjects: 285
Study 24557028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 446
Study 24557028 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone
Number of subjects: 446
Study 24557028 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone
Number of subjects: 446
Study 24557028 — intervention group
Group type: EXPERIMENTAL
Intervention: Race/Ethnicity (Black)
Number of subjects: 446
Study 24557028 — intervention group
Group type: EXPERIMENTAL
Intervention: Race/Ethnicity (White)
Number of subjects: 446
Study 24095300 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab (4 mg/kg load, then 2 mg/kg intravenously weekly until surgery)
Number of subjects: 529
Study 24095300 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib (1250 mg orally daily until surgery)
Number of subjects: 529
Study 24095300 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly trastuzumab plus lapatinib (750 mg orally daily until surgery)
Number of subjects: 529
Study 21419792 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (IV) group, n=55
Number of subjects: 121
Study 21419792 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (CG), n=20
Number of subjects: 121
Study 18566882 — intervention group
Group type: EXPERIMENTAL
Intervention: LEGO therapy
Number of subjects: 0
Study 18566882 — intervention group
Group type: EXPERIMENTAL
Intervention: SULP
Number of subjects: 0
Study 18566882 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 16989205 — intervention group
Group type: EXPERIMENTAL
Intervention: SMC electrophoresis of peat mud diluted with distilled water
Number of subjects: 65
Study 15153818 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (Control group)
Number of subjects: 23
Study 15153818 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of fibrin (Group 2)
Number of subjects: 23
Study 15153818 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin composition with deferoxamine and VEGF(165) (Group 3)
Number of subjects: 23
Study 10955016 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE inhibitors
Number of subjects: 0
Study 10955016 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrates
Number of subjects: 0
Study 8636309 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg finasteride daily for 6-18 days (group 1)
Number of subjects: 26
Study 8636309 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg finasteride daily for 23-73 days (group 2)
Number of subjects: 26
Study 8636309 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg finasteride daily for 3 months to 4 years (group 3)
Number of subjects: 26
Study 8636309 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 26
Study 1308375 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg midazolam administered rectally as premedication
Number of subjects: 40
Study 1308375 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.35 mg/kg midazolam administered rectally as premedication
Number of subjects: 40
Study 1308375 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 mg/kg midazolam administered rectally as premedication
Number of subjects: 40
Study 1308375 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study 3542771 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml Novaluzid 1 and 3 hours after each meal and at bedtime for 2 weeks
Number of subjects: 186
Study 3542771 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml Novaluzid 1 and 3 hours after each meal and at bedtime for 4 weeks
Number of subjects: 186
Study 29533244 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin rigid contact lens (CL)
Number of subjects: 0
Study 29533244 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal protective agent (CPA)
Number of subjects: 0
Study 29533244 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (BSS)
Number of subjects: 0
Study 27193613 — intervention group
Group type: EXPERIMENTAL
Intervention: HH intervention including: HH products, training about HH guidelines, two team training sessions, reminders and cues for action (posters/stickers)
Number of subjects: 795
Study 27193613 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual practice)
Number of subjects: 795
Study 27193613 — intervention group
Group type: EXPERIMENTAL
Intervention: HH intervention
Number of subjects: 795
Study 24962039 — intervention group
Group type: EXPERIMENTAL
Intervention: Active moxibustion
Number of subjects: 110
Study 24962039 — intervention group
Group type: COMPARATOR
Intervention: Sham moxibustion
Number of subjects: 110
Study 22955728 — intervention group
Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine (30g alcohol/day)
Number of subjects: 67
Study 22955728 — intervention group
Group type: COMPARATOR
Intervention: Alcoholic red wine (30g alcohol/day)
Number of subjects: 67
Study 22955728 — intervention group
Group type: COMPARATOR
Intervention: Gin (30g alcohol/day)
Number of subjects: 67
Study 20072067 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional injury prevention program
Number of subjects: 65
Study 20072067 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 20072067 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric injury prevention program
Number of subjects: 65
Study 18541610 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral dexamethasone (single dose)
Number of subjects: 7
Study 18541610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 18373136 — intervention group
Group type: EXPERIMENTAL
Intervention: EMR-based intervention with standardized medication review
Number of subjects: 620
Study 18373136 — intervention group
Group type: EXPERIMENTAL
Intervention: EMR-based intervention
Number of subjects: 620
Study 15499252 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight corneal reshaping (OCR) lenses
Number of subjects: 74
Study 15499252 — intervention group
Group type: COMPARATOR
Intervention: Soft daily-wear lenses
Number of subjects: 74
Study 11733883 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous measurements of blood gases
Number of subjects: 81
Study 9230162 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 9230162 — intervention group
Group type: COMPARATOR
Intervention: No Propranolol
Number of subjects: 0
Study 8423429 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic treatment including side-lying manipulation (n = 17)
Number of subjects: 36
Study 8423429 — intervention group
Group type: COMPARATOR
Intervention: Detuned ultrasound, application of a cold pack, and gentle soft tissue massage (n = 19)
Number of subjects: 36
Study 3616852 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (3 g in a single intramuscular injection)
Number of subjects: 18
Study 3616852 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g im daily for two days)
Number of subjects: 18
Study 3616852 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g im daily for five days)
Number of subjects: 18
Study 3616852 — intervention group
Group type: COMPARATOR
Intervention: Benzathine penicillin (2.4 X 10(6) units in a single im injection)
Number of subjects: 18
Study 30841745 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based caregiver support toolkit
Number of subjects: 0
Study 30641838 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT probability of poor outcome at admission
Number of subjects: 166
Study 30641838 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial plasma concentrations of interleukin (IL)‐6
Number of subjects: 166
Study 30641838 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial plasma concentrations of interleukin (IL)‐8
Number of subjects: 166
Study 30641838 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial plasma concentrations of interleukin (IL)‐10
Number of subjects: 166
Study 30641838 — intervention group
Group type: EXPERIMENTAL
Intervention: MODS following TBI
Number of subjects: 166
Study 30641838 — intervention group
Group type: EXPERIMENTAL
Intervention: SOFA score
Number of subjects: 166
Study 28391736 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus brevis KB290 + β-carotene
Number of subjects: 0
Study 28391736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25412093 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exchange
Number of subjects: 473
Study 25412093 — intervention group
Group type: COMPARATOR
Intervention: CO2 insufflation
Number of subjects: 473
Study 24079752 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant S‐1 therapy
Number of subjects: 0
Study 24079752 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 21816543 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion in combination with health education counseling
Number of subjects: 540
Study 21816543 — intervention group
Group type: COMPARATOR
Intervention: Non-menthol smoking (control group)
Number of subjects: 540
Study 19967490 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (2 x 100‐mg capsules) and leucovorin (1 x 25‐mg tablet) taken after a low-fat meal
Number of subjects: 12